Neuromyelitis optica spectrum disorder
ORPHA:71211DiseaseMultigenic/multifactorialAdolescent, Adult, Childhood, Elderly
Фенотипы (HPO)17
Очень частый (80–99%)10
HP:0000009Functional abnormality of the bladder
HP:0000572Visual loss
HP:0002529Neuronal loss in central nervous system
HP:0003474Somatic sensory dysfunction
HP:0010550Paraplegia
HP:0011096Peripheral demyelination
HP:0012486Myelitis
HP:0030057Autoimmune antibody positivity
HP:0100653Optic neuritis
HP:0200026Ocular pain
Частый (30–79%)2
HP:0012443Abnormality of brain morphology
HP:0033342Anti-aquaporin 4 antibody positivity
Периодический (5–29%)5
HP:0002018Nausea
HP:0002878Respiratory failure
HP:0012229CSF pleocytosis
HP:0032492Anti-myelin oligodendrocyte glycoprotein antibody positivity
HP:0100247Recurrent singultus
Эпидемиология31
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.73 | Martinique | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.054 | Austria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.1877 | Worldwide | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.071 | Worldwide | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.7 | Austria | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.08 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.43 | United Kingdom | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.09 | Netherlands | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.063 | Spain | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.89 | Spain | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.07 | Denmark | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.09 | Denmark | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.079 | Sweden | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.04 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.132 | Hungary | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.91 | Hungary | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.037 | Australia | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.7 | Australia | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.07 | United States | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.9 | United States | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.495 | India | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.495 | Canada | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | India | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.42 | Japan | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.39 | Malaysia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.94 | Malaysia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.51 | Iran, Islamic Republic of | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.053 | Cuba | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.52 | Cuba | Value and class |
| Point prevalence | 1-5 / 10 000 | 10 | Martinique | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.285 | Costa rica | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)